Rebiotix Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Rebiotix Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH479974D
  • |
  • Pages: 23
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Rebiotix Inc (Rebiotix), formerly MikrobEX Inc is a clinical stage biotechnology company that develops treatments for debilitating diseases. The company targets various disease conditions using drugs based on its microbiota restoration therapy platform. It lead product candidate RBX2660 is used to treat recurrent Clostridium difficile infection is a non-antibiotic liquid microbial suspension. Rebiotix's RBX7455 is an oral formulation in a lyophilized form. The company partners with physicians to evaluate the use of MRT for ulcerative colitis, hepatic encephalopathy and multi drug-resistant organisms. Rebiotix is headquartered in Roseville, Minnesota, the US.

Rebiotix Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Rebiotix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Rebiotix Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Rebiotix Raises 8.5 Million in Venture Financing 10

Rebiotix Raises USD25 Million in Series B Financing 11

Partnerships 12

Microbiome Insights and Rebiotix Enter into Collaboration Agreement 12

Rebiotix Enters into Agreement with CoreBiome 13

Acquisition 14

Ferring Pharma Acquires Rebiotix 14

Rebiotix Inc-Key Competitors 15

Rebiotix Inc-Key Employees 16

Rebiotix Inc-Locations And Subsidiaries 17

Head Office 17

Recent Developments 18

Corporate Communications 18

Mar 12, 2018: Rebiotix's Chief Scientific Officer, Ken Blount, Ph.D., to Present at Microbiome Therapeutics Europe 18

Jun 20, 2017: Rebiotix Continues Management Team Expansion with Appointment of Greg Fluet as Chief Business Officer 19

Product News 20

Apr 11, 2017: Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridium difficile 20

Other Significant Developments 21

Oct 03, 2018: Baylor, Rebiotix find patient microbiome signatures that differentiate disease states 21

Jan 09, 2018: Rebiotix Highlights 2017 Achievements and 2018 Objectives 22

Appendix 23

Methodology 23

About GlobalData 23

Contact Us 23

Disclaimer 23

List of Figures

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Rebiotix Inc, Pharmaceuticals & Healthcare, Key Facts 2

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Rebiotix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Rebiotix Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Rebiotix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Rebiotix Raises 8.5 Million in Venture Financing 10

Rebiotix Raises USD25 Million in Series B Financing 11

Microbiome Insights and Rebiotix Enter into Collaboration Agreement 12

Rebiotix Enters into Agreement with CoreBiome 13

Ferring Pharma Acquires Rebiotix 14

Rebiotix Inc, Key Competitors 15

Rebiotix Inc, Key Employees 16

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Rebiotix Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17198
Site License
USD 500 INR 34395
Corporate User License
USD 750 INR 51593

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com